Moreover, our previous results showed that CSF Tau N368/Tau ratios in AD patients better reflect the individual cognitive deficits and Tau pathologies than p-Tau 181 and p-Tau217 levels [49, 50]. The gene discussed is MAPT; the disease is Alzheimer disease.